# Evaluate RCN3028 in Treatment of Drug-Induced VMS in Breast Cancer

> **NCT06161792** · PHASE2 · TERMINATED · sponsor: **Yung Shin Pharm. Ind. Co., Ltd.** · enrollment: 10 (actual)

## Conditions studied

- Hot Flashes
- Breast Cancer

## Interventions

- **DRUG:** 0.8 mg RCN3028
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06161792
- **Lead sponsor:** Yung Shin Pharm. Ind. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-07
- **Primary completion:** 2022-03-14
- **Final completion:** 2022-04-20
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Difficulty in recruiting breast cancer patients, leading to a slow rate of case enrollment.
- **Last updated:** 2023-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06161792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06161792, "Evaluate RCN3028 in Treatment of Drug-Induced VMS in Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06161792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*